Sharemaestro company-news research for Rallybio Corp (RLYB), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Insufficient evidence
Company news sentiment
Latest RLYB news and sentiment
Rallybio Corp
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
No current company-news score
No company-specific headline in the last 30 days currently passes the date and relevance checks. The dash means no score; it is not a neutral observation.
Observed headline tone50/100
→
Published 30-day score50/100
Latest source headline
Form 4 Rallybio Corp For: 9 October By Investing.com
Investing.com Nigeria · 09 Oct 2026 05:10
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
Available information
6 current stories are mapped specifically to RLYB.
Why there is no score
The stories agree, but freshness-weighted evidence is only 0.000.
Confidence is 0/100, below the threshold for a firm score.
—/100
News scoreNo qualifying directional evidence
0/100
Confidencethin evidence
0%/100
Company news6 company stories
100/100
Story agreement0/100 difference
News history
Daily score and story count over 30 days
15 Sep30 Sep14 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.0 after freshness weightingSource breadth0
0 independent publishersCompany relevance0
share tied directly to this companyFreshness15
recency-weighted evidenceAgreement100
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
No sufficiently fresh, directly relevant company news is available for a price comparison.
26 completed price weeks20 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202650USD 17.02-0.4%
02 Oct 202650USD 17.08+2.8%
25 Sep 202650USD 16.62-3.3%
18 Sep 202650USD 17.19+1.9%
11 Sep 202649USD 16.875-0.3%
04 Sep 202649USD 16.925+0.7%
28 Aug 202647USD 16.81-0.1%
21 Aug 202650USD 16.83-0.9%
Insufficient evidence
News subjects
What is shaping the score
Market update503 stories · 50%
Deals and strategy502 stories · 33%
Regulatory and legal501 stories · 17%
Source mix
Where the evidence comes from
Investing.com Nigeria502 stories · 33%
Stock Titan502 stories · 33%
Investing.com South Africa501 stories · 17%
Investing.com India501 stories · 17%
Recurring subjects
Subjects appearing most often
Financial Markets5Life Sciences4Finance3Mergers And Acquisitions2IPO1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
23 May50 neutral14 Oct 00:58
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 14 Oct 00:58 | 50 | +0 | 0/100 (0) | 6 (-1) | Insufficient |
| 09 Oct 23:59 | 50 | +0 | 0/100 (0) | 7 (0) | Insufficient |
| 02 Oct 23:59 | 50 | +0 | 0/100 (0) | 7 (+2) | Insufficient |
| 29 Sep 23:59 | 50 | +0 | 0/100 (-17) | 5 (-2) | Insufficient |
| 15 Sep 23:59 | 50 | +1 | 17/100 (-1) | 7 (-6) | Provisional |
| 10 Sep 23:59 | 49 | +0 | 18/100 (-4) | 13 (-6) | Provisional |
| 04 Sep 23:59 | 49 | +1 | 22/100 (-5) | 19 (-1) | Provisional |
| 30 Aug 23:59 | 48 | +1 | 27/100 (+4) | 20 (-2) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 6 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
No directional evidence to attribute yet
Company news can still be read below. Influence bars appear when a current story qualifies for the directional score.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
Form 4 Rallybio Corp For: 9 October By Investing.com
This article from Investing.com is a brief notice about a Form 4 filing for Rallybio Corp on October 9. It appears to be a placeholder or very short news item, possibly indicating an insider transaction or significant corporate event that requires public disclosure. The main content beyon…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article from Investing.com is a brief notice about a Form 4 filing for Rallybio Corp on October 9. It appears to be a placeholder or very short news item, possibly indicating an insider transaction or significant corporate event that requires public disclosure. The main content beyond the headline consists primarily of financial market data and unrelated popular news snippets.
- Published
- 09 Oct 2026 05:10
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 4.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Form 4 Rallybio Corp For: 2 October By Investing.com
The article reports on a Form 4 filing for Rallybio Corp on October 2nd. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders, such as officers, directors, and beneficial owners of more than 10% of a company's stock, whenever t…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
The article reports on a Form 4 filing for Rallybio Corp on October 2nd. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders, such as officers, directors, and beneficial owners of more than 10% of a company's stock, whenever they trade securities in that company. This specific filing is for Rallybio Corp, which saw a 1.91% increase in its RLYB stock symbol.
- Published
- 02 Oct 2026 10:16
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Deals and strategyNot used in direction
The proposed Avenzo merger would pair $215M financing with an ownership split for Rallybio (RLYB) holders.
Rallybio (RLYB) is proposing a merger with Avenzo Therapeutics, Inc., a clinical-stage biotechnology company, which would include $215 million in concurrent financing. Post-merger, Rallybio's pre-merger holders are estimated to own 2.8% of the combined company, while Avenzo's pre-merger h…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Rallybio (RLYB) is proposing a merger with Avenzo Therapeutics, Inc., a clinical-stage biotechnology company, which would include $215 million in concurrent financing. Post-merger, Rallybio's pre-merger holders are estimated to own 2.8% of the combined company, while Avenzo's pre-merger holders would own 56.6%, and new financing investors 40.6%. The merger is contingent on several approvals, including Rallybio stockholder approval and Nasdaq listing confirmation, and would result in Rallybio being renamed Avenzo Therapeutics, Inc.
- Published
- 02 Oct 2026 07:58
- News subject
- Deals and strategy
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 11.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceMergers And Acquisitions
—Unscored
Regulatory and legalNot used in direction
Form 4 Rallybio Corp For: 28 September By Investing.com
This article announces the filing of Form 4 for Rallybio Corp on September 28. It is a brief news item indicating a financial regulatory update concerning the company. The publication date is September 29, 2026.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article announces the filing of Form 4 for Rallybio Corp on September 28. It is a brief news item indicating a financial regulatory update concerning the company. The publication date is September 29, 2026.
- Published
- 29 Sep 2026 03:32
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
FinanceFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Form 4 Rallybio Corp For: 28 September
This article reports on a Form 4 filing for Rallybio Corp for September 28th. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of a company's securities by insiders. The article provides no further details about the specific transactions.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article reports on a Form 4 filing for Rallybio Corp for September 28th. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of a company's securities by insiders. The article provides no further details about the specific transactions.
- Published
- 29 Sep 2026 01:18
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 15.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial Markets
—Unscored
Deals and strategyNot used in direction
Rallybio (NASDAQ: RLYB) holders expected to own 2.8% of new Avenzo
Rallybio Corporation (NASDAQ: RLYB) has filed an amended Form S-4 detailing its all-stock merger with Avenzo Therapeutics, Inc. Existing Rallybio stockholders are projected to own approximately 2.8% of the combined company, with Avenzo stockholders (excluding new investors) owning about 5…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Rallybio Corporation (NASDAQ: RLYB) has filed an amended Form S-4 detailing its all-stock merger with Avenzo Therapeutics, Inc. Existing Rallybio stockholders are projected to own approximately 2.8% of the combined company, with Avenzo stockholders (excluding new investors) owning about 56.6%, and concurrent financing investors holding 40.6%. Rallybio plans to distribute its net cash, estimated at $82.2 million as of August 15, 2026, to current stockholders through cash distributions and contingent value rights tied to legacy asset monetization.
- Published
- 15 Sep 2026 19:07
- News subject
- Deals and strategy
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceFinancial MarketsIPOLife SciencesMergers And Acquisitions
Earlier company news
RLYB news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 57 older RLYB headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to RLYB, but the headline and available text are not mainly about Rallybio Corp. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of RLYB sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.